SCLX (Scilex Holding Co) ROC %: -33.73% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCLX Scilex Holding Co SCLX
55 GF Score
Price $7.95
GF Value $5.90
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Scilex Holding Co ROC %?

Scilex Holding Co SCLX +2.15% 55 ROC % is -33.73% as of Mar. 2026. GuruFocus rates SCLX with a GF Score™ of 55/100 and a GF Value™ of $5.90 (Significantly Overvalued). The stock has 7 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Scilex Holding Co's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -33.73%.

As of today (2026-07-22), Scilex Holding Co's WACC % is 18.64%. Scilex Holding Co's ROC % is -108.97% (calculated using TTM income statement data). Scilex Holding Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Scilex Holding Co  (NAS:SCLX) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Scilex Holding Co's WACC % is 18.64%. Scilex Holding Co's ROC % is -108.97% (calculated using TTM income statement data). Scilex Holding Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Scilex Holding Co ROC % Related Terms


Scilex Holding Co ROC % Historical Data

* Premium members only.

The historical data trend for Scilex Holding Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scilex Holding Co ROC % Chart

Scilex Holding Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
Get a 7-Day Free Trial -35.59 -59.25 -94.93 -72.56 -105.93

Scilex Holding Co Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -119.51 -85.52 -363.17 -40.65 -33.73
SCLX
55GF Score
Scilex Holding Co SCLX
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scilex Holding Co ROC % Calculation

Scilex Holding Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-272.304 * ( 1 - 0% )/( (91.558 + 422.569)/ 2 )
=-272.304/257.0635
=-105.93 %

where

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=364.981 - 387.706 - ( 10.981 - max(0, 483.652 - 38.358+10.981))
=422.569

Scilex Holding Co's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-128.676 * ( 1 - 0% )/( (422.569 + 340.387)/ 2 )
=-128.676/381.478
=-33.73 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=364.981 - 387.706 - ( 10.981 - max(0, 483.652 - 38.358+10.981))
=422.569

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -33.73% mean?
Scilex Holding Co (SCLX) has a ROC % of -33.73% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Scilex Holding Co and its competitors.
Is Scilex Holding Co's ROC % too high?
Scilex Holding Co's current ROC % is -33.73%. Overall, Scilex Holding Co has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Scilex Holding Co's ROC % compare to MIRA and NSRX?
Scilex Holding Co's ROC % of -33.73% can be compared against companies in the Drug Manufacturers industry. The industry median ROC % is 4.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Drug Manufacturers company?
The median ROC % among Drug Manufacturers companies is 4.46, based on 988 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Scilex Holding Co and its competitors. For the Drug Manufacturers industry, the median ROC % is 4.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scilex Holding Co's current ROC % is -33.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scilex Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Scilex Holding Co (SCLX) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.90, compared to a current price of $7.95 — trading 34.7% above its estimated fair value. The current ROC % is -33.73%. Scilex Holding Co's overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Scilex Holding Co (SCLX), the current ROC % is -33.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scilex Holding Co (SCLX) Overvalued in 2026?

Based on GuruFocus' analysis, Scilex Holding Co stock appears to be overvalued. The current stock price of $7.95 is trading 34.7% above its estimated GF Value™ of $5.90. GuruFocus considers Scilex Holding Co to be Significantly Overvalued.

Key valuation signals for SCLX:

  • ROC %: -33.73%
  • GF Value™: $5.90 vs. price of $7.95 (34.7% above fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the SCLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Scilex Holding Co Business Description

Other Exchanges D8B0:Germany
Address 960 San Antonio Road, Palo Alto, CA, USA, 94303
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
55GF Score

Get the complete analysis for SCLX

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.95
Price
$5.90
GF Value